New cellular therapies: Is there a role for transfusion services?

Reesink, H. W.; Panzer, Sarah E.; Dettke, Markus; Gabriel, Christian; Lambermont, Micheline; Deneys, Véronique; Sondag, D.; Dickmeiss, Ebbe; Fischer‐Nielsen, Anne; Korhonen, Matti; Krusius, Tom; Ali, Anita M.; Tiberghien, Pierre; Schrezenmeier, Hubert; Tonn, Torsten; Seifried, Erhard; Klüter, H.; Politis, C.; Stavropoulou‐Gioka, A.; Parara, M.; Flesland, Øystein; Nascimento, Fátima; Balint, Bela; Mariń, P; Bart, Thomas; Chen, Frederick; Pamphilon, Derwood

doi:10.1111/j.1423-0410.2009.01184.x

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to do so, the collected data will be available for the T&C working group to distribute and use in reports and meetings. Advanced therapy medicinal products (ATMPs) were excluded, as experience in the area of ATMPs is only just beginning to emerge and a survey of more established tissues and cells operations was considered more appropriate at this time.…”

Section: Introductionmentioning

confidence: 99%

Collection, processing and testing of bone, corneas, umbilical cord blood and haematopoietic stem cells by European Blood Alliance members

et al. 2013

Self Cite

View full text Add to dashboard Cite

Estimated percentages of tissue and cell banking covered by EBA member blood banks as a proportion of all collections of each individual country varied markedly. There were also major differences in the amounts of products collected and discarded and in proportions tissues provided for grafting. However, discarding of certain collections also reflects the practice of increasing the likelihood of the very best units being used for transplantation. Harmonization of possible practices should focus on matching supply with demand and on identifying the most efficient operators. This could allow for the development of practices for minimizing unnecessary collections.

show abstract

Section: Introductionmentioning

confidence: 99%

Collection, processing and testing of bone, corneas, umbilical cord blood and haematopoietic stem cells by European Blood Alliance members

et al. 2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…Quite naturally a significant role for transfusion services in this field of new cellular therapies arises, considering their long-standing expertise in classical blood productions, quality control, storage facilities and transport logistics, and with regard to their extensive clinical network [85,86]. Thus, an association between blood centers and GMP-clean room facilities would be of benefit, since production steps of these novel cell preparations are not fully restricted to closed systems [87].…”

Section: Nk-92 - a Third-party Nk Cell Drugmentioning

confidence: 99%

“…However, high operational expenditures for such facilities need to be taken into account [86]. Marketing of such ‘advanced medicinal products', is a complex process which in Europe is overseen by the European Medicines Agency [85,88]. Hence, practicability and cost factors pose limits to the implementation of such new types of personalized medicines in blood centers.…”

Section: Nk-92 - a Third-party Nk Cell Drugmentioning

confidence: 99%

Natural Killer Cells for Therapy of Leukemia

Suck

Linn

Tonn

2016

Transfus Med Hemother

View full text Add to dashboard Cite

Clinical application of natural killer (NK) cells against leukemia is an area of intense investigation. In human leukocyte antigen-mismatched allogeneic hematopoietic stem cell transplantations (HSCT), alloreactive NK cells exert powerful anti-leukemic activity in preventing relapse in the absence of graft-versus-host disease, particularly in acute myeloid leukemia patients. Adoptive transfer of donor NK cells post-HSCT or in non-transplant scenarios may be superior to the currently widely used unmanipulated donor lymphocyte infusion. This concept could be further improved through transfusion of activated NK cells. Significant progress has been made in good manufacturing practice (GMP)-compliant large-scale production of stimulated effectors. However, inherent limitations remain. These include differing yields and compositions of the end-product due to donor variability and inefficient means for cryopreservation. Moreover, the impact of the various novel activation strategies on NK cell biology and in vivo behavior are barely understood. In contrast, reproduction of the third-party NK-92 drug from a cryostored GMP-compliant master cell bank is straightforward and efficient. Safety for the application of this highly cytotoxic cell line was demonstrated in first clinical trials. This novel ‘off-the-shelf' product could become a treatment option for a broad patient population. For specific tumor targeting chimeric-antigen-receptor-engineered NK-92 cells have been designed.

show abstract

Concise Review: Expanding Roles for Hematopoietic Cellular Therapy and the Blood Transfusion Services

Hodby

Pamphilon

2011

Stem Cells

View full text Add to dashboard Cite

Hematopoietic stem cells (HSCs) have remained at the forefront of stem cell research for the past 50 years, since the therapeutic potential of bone marrow transplantation was realized. Uniquely, among stem and progenitor cells, research progress has been made in parallel between the laboratory benchtop and hospital bedside during this period. Integral to this work has been the role of the transfusion medicine services in the collection, storage, and processing of HSCs. The next decade promises to bring further developments: with new fields of cellular therapies, stem cell vaccination, and stem cell drug testing opening up. This article summarizes exciting areas of research concerning the behavior and potential clinical applications of HSCs. For the purposes of clarity, we describe in turn the trafficking and transfer of HSCs; ex vivo expansion of HSC units from different sources; and finally, applications of specifically selected subsets of hematopoietic cells and their progeny.

show abstract

New cellular therapies: Is there a role for transfusion services?

Cited by 5 publications

References 0 publications

Collection, processing and testing of bone, corneas, umbilical cord blood and haematopoietic stem cells by European Blood Alliance members

Collection, processing and testing of bone, corneas, umbilical cord blood and haematopoietic stem cells by European Blood Alliance members

Natural Killer Cells for Therapy of Leukemia

Concise Review: Expanding Roles for Hematopoietic Cellular Therapy and the Blood Transfusion Services

Contact Info

Product

Resources

About